Lumos Appoints Henry Schein as US Distributor for FebriDx®
12 February 2024
Lumos Diagnostics (ASX: LDX) has today announced it has signed an agreement with Henry Schein, Inc. to distribute FebriDx® in the United States.
Henry Schein, the world’s largest provider of health care solutions to office-based dental and medical practitioners, currently distributes the FebriDx test in the UK, Spain, Portugal, and the Netherlands. By expanding reach of this product in the US, Henry Schein can enhance its current diagnostic offerings to US customers, which are supported by Henry Schein’s dedicated Lab Services team, comprised of specialists throughout the country.
CEO and MD of Lumos Diagnostics, Doug Ward, commented:
“We are delighted that Henry Schein has expanded its distribution coverage for our FebriDx test to include the United States. The US is the biggest commercial opportunity for FebriDx due to the routine use of point-of-care tests in standard clinical workflow and established reimbursement. We believe FebriDx has a unique role in ensuring that antibiotics are only given to patients who are likely to benefit from them. As Henry Schein has been an excellent distribution partner for Lumos in Europe, we are very excited to have them as our distribution partner in the world’s largest market for point-of-care testing.”
Click here to read the announcement
Henry Schein, the world’s largest provider of health care solutions to office-based dental and medical practitioners, currently distributes the FebriDx test in the UK, Spain, Portugal, and the Netherlands. By expanding reach of this product in the US, Henry Schein can enhance its current diagnostic offerings to US customers, which are supported by Henry Schein’s dedicated Lab Services team, comprised of specialists throughout the country.
CEO and MD of Lumos Diagnostics, Doug Ward, commented:
“We are delighted that Henry Schein has expanded its distribution coverage for our FebriDx test to include the United States. The US is the biggest commercial opportunity for FebriDx due to the routine use of point-of-care tests in standard clinical workflow and established reimbursement. We believe FebriDx has a unique role in ensuring that antibiotics are only given to patients who are likely to benefit from them. As Henry Schein has been an excellent distribution partner for Lumos in Europe, we are very excited to have them as our distribution partner in the world’s largest market for point-of-care testing.”
Click here to read the announcement
